| Literature DB >> 35915440 |
Ling Zhang1, Jiong-Bin Lin1, Ming Jia1, Chen-Cai Zhang1, Rong Xu1, Le Guo1, Xiao-Jia Lin1, Quan-Shi Wang2.
Abstract
BACKGROUND: To predict the histological grade and microvascular invasion (MVI) in patients with HCC.Entities:
Keywords: Hepatocellular carcinoma; Histological grade; Magnetic resonance imaging; Microvascular
Mesh:
Year: 2022 PMID: 35915440 PMCID: PMC9341046 DOI: 10.1186/s12876-022-02449-w
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 2.847
Fig. 1A 50-year-old man presented with low-grade HCC with MVI. A Unevenly high signals on T2WI; B, C Heterogeneous enhancement (black arrow) in the left lobe of liver in the arterial and delayed phases of GD-BOPTA–enhanced MRI; D Non-smooth tumor edge and peritumoral hypo-signal intensity (white arrow) in the hepatobiliary phase
Fig. 2A 43-year-old male with High-grade HCC without MVI. A Unevenly high signals on T2WI; B, C In the arterial phase of GD-Bopta-enhanced MRI, the lesions showed obvious uneven enhancement, and the enhancement was weakened in the delayed phase. D The mass at the hepatobiliary phase has low signal intensity, with a peritumor area of low signal (white arrow)
Comparison of patient characteristics according to vascular invasion
| Characteristics | Total | MVI | Grade | ||||
|---|---|---|---|---|---|---|---|
| Negative | Positive | Low | High | ||||
| Age | 175 | 54.339 (10.584) | 53.383 (10.742) | 0.573 | 52.250 (10.606) | 54.677 (10.587) | 0.1780 |
| Recurrence (months) | 175 | 30.67 ± 23.43 | 22.18 ± 18.30 | 25.97 ± 20.67 | 21.72 ± 18.92 | 0.186 | |
| Metastasis (months) | 175 | 30.08 ± 23.67 | 21.76 ± 18.96 | 26.03 ± 21.33 | 20.22 ± 18.79 | 0.077 | |
| HBsAg | 0.080 | 0.590 | |||||
| Negative | 26 | 21 (80.77) | 5 (19.23) | 6 (23.08) | 20 (76.92) | ||
| Positive | 149 | 94 (63.09) | 55 (36.91) | 42 (28.19) | 107 (71.81) | ||
| HBeAg | 0.706 | 0.266 | |||||
| Negative | 117 | 78 (66.67) | 39 (33.33) | 29 (24.79) | 88 (75.21) | ||
| Positive | 58 | 37 (63.79) | 21 (36.21) | 19 (32.76) | 39 (67.24) | ||
| Cirrhosis | 0.522 | ||||||
| Negative | 46 | 32 (69.57) | 14 (30.43) | 6 (13.04) | 40 (86.96) | ||
| Positive | 129 | 83 (64.34) | 46 (35.66) | 42 (32.56) | 87 (67.44) | ||
| AFP (ng/L) | |||||||
| > 0 < 20 | 81 | 63 (77.78) | 18 (22.22) | 30(37.04) | 51 (62.96) | ||
| > 20 < 400 | 58 | 36 (62.07) | 22 (37.93) | 11 (18.97) | 47 (81.03) | ||
| ≥ 400 | 36 | 16 (44.44) | 20 (55.56) | 7 (19.44) | 29 (80.56) | ||
| Tumor Number | |||||||
| Single | 145 | 102 (70.34) | 43 (29.66) | 45 (31.03) | 100 (68.97) | ||
| Multiple | 30 | 13 (43.33) | 17 (56.67) | 3 (10.00) | 27 (90.00) | ||
| Tumor size (cm) | 0.979 | ||||||
| < 5 | 131 | 92 (70.23) | 39 (29.77) | 36 (27.48) | 95 (72.52) | ||
| ≥ 5 | 44 | 23 (52.27) | 21 (47.73) | 12 (27.27) | 32 (72.73) | ||
| Capsule | |||||||
| Negative | 117 | 70 (59.83) | 47 (40.17) | 25 (21.37) | 92 (78.63) | ||
| Positive | 58 | 45 (77.59) | 13 (22.41) | 23 (39.66) | 35 (60.34) | ||
| Lipid | 0.609 | 0.078 | |||||
| Negative | 121 | 81 (66.94) | 40 (33.06) | 38 (31.40) | 83 (68.60) | ||
| Positive | 54 | 34 (62.96) | 20 (37.04) | 10 (18.52) | 44 (81.48) | ||
| Arterial rim enhancement | 0.451 | ||||||
| Negative | 94 | 72 (76.60) | 22 (23.40) | 28 (29.79) | 66 (70.21) | ||
| Positive | 81 | 43 (53.09) | 38 (46.91) | 20 (24.69) | 61 (75.31) | ||
| Arterial peritumoral enhancement | 0.396 | ||||||
| Negative | 152 | 111 (73.03) | 41 (26.97) | 40 (26.32) | 112 (73.68) | ||
| Positive | 23 | 4 (17.39) | 19 (82.61) | 8 (34.78) | 15 (65.22) | ||
| Tumor margin | 0.883 | ||||||
| Smooth | 75 | 61 (81.33) | 14 (18.67) | 21 (28.00) | 54 (72.00) | ||
| Non-smooth | 100 | 54 (54.00) | 46 (46.00) | 27 (27.00) | 73 (73.00) | ||
| Tumor hypointensity on HBP | 0.291 | 0.177 | |||||
| Yes | 161 | 104 (64.60) | 57 (35.40) | 42 (26.09) | 119 (73.91) | ||
| No | 14 | 11 (78.57) | 3 (21.43) | 6 (42.86) | 8 (57.14) | ||
| Peritumoral hypointensity on HBP | 0.178 | ||||||
| Absent | 146 | 106 (72.60) | 40 (27.40) | 43 (29.45) | 103 (70.55) | ||
| Present | 29 | 9 (31.03) | 20 (68.97) | 5 (17.24) | 24 (82.76) | ||
| 0.854 | |||||||
| Round | 58 | 40 (68.97) | 18 (31.03) | 23 (39.66) | 35 (60.34) | ||
| Oval | 20 | 14 (70.00) | 6 (30.00) | 6 (30.00) | 14 (70.00) | ||
| Lobulated | 65 | 41 (63.08) | 24 (36.92) | 11 (16.92) | 54 (83.08) | ||
| I rregular | 32 | 20 (62.50) | 12 (37.50) | 8 (25.00) | 24 (75.00) | ||
Figs. 3–6Survival analysis of recurrence and metastasis in MVI positive and negative groups (3–4), Grade-low and Grade-high groups (5–6)
Univariate and multivariate analyses of preoperative MR imaging findings in predicting MVI or Grade
| Univariate analysis (MVI) | multivariate analyses (MVI) | Univariate analysis (grade) | multivariate analyses (grade) | |||||
|---|---|---|---|---|---|---|---|---|
| Age | 0.991 (0.963, 1.021) | 0.571 | 1.022 ( 0.990, 0.055) | 0.178 | ||||
| Sex | 1.844 (0.812, 4.185) | 0.143 | 0.520 (0.223, 1.210) | 0.129 | ||||
| Lipid | 1.191 (0.61, 2.327) | 0.609 | 2.014 (0.917, 4.424) | 0.081 | 2.551 (0.96, 6.78) | 0.06 | ||
| Tumor Size | 2.154 (1.069, 4.338) | 0.032 | 5.174 (1.625, 16.477) | 1.011 (0.47, 2.175) | 0.979 | |||
| > 20, ≤ 400 | 2.139 (1.015, 4.508) | 0.046 | 1.845 (0.729, 4.673) | 0.196 | 2.513 (1.133, 5.574) | 0.023 | 1.325 (0.529, 3.321) | 0.548 |
| > 400 | 4.375 (1.888, 10.14) | 0.001 | 2.554 (0.84, 7.765) | 0.098 | 2.437 (0.951, 6.242) | 0.063 | 2.553 (0.804, 8.114) | 0.112 |
| HBsAg | 2.457 (0.877, 6.887) | 0.087 | 4.373 (1.193, 16.029) | 0.764 (0.287, 2.036) | 0.591 | |||
| HBeAg | 1.135 (0.587, 2.194) | 0.706 | 0.676 (0.339, 1.349) | 0.267 | ||||
| Tumor Number | 3.102 (1.386, 6.94) | 0.006 | 4.79 (1.565, 14.661) | 4.05 (1.168, 14.046) | 0.027 | 5.948 (1.345, 26.298) | ||
| Cirrhosis | 1.267 (0.614, 2.613) | 0.522 | 0.311 (0.122, 0.791) | 0.014 | 0.252 (0.088, 0.719) | |||
| Capsule | 0.43 (0.21, 0.883) | 0.022 | 0.293 (0.098, 0.877) | 0.414 (0.208, 0.822) | 0.012 | 0.289 (0.123, 0.68) | ||
| Arterial rim enhancement | 2.892 (1.515, 5.523) | 0.001 | 2.141 (0.945, 4.853) | 0.068 | 1.294 (0.661, 2.532) | 0.452 | ||
| Arterial peritumoral enhancement | 12.86 (4.129, 40.055) | < 0.001 | 5.02 (1.219, 20.68) | 0.67 (0.264, 1.699) | 0.398 | |||
| Tumor margin | 3.712 (1.84, 7.485) | < 0.001 | 4.12 (1.621, 10.474) | 1.052 (0.538, 2.055) | 0.883 | |||
| Tumor hypointensity on HBP | 0.498 (0.133, 1.857) | 0.299 | 0.47 (0.154, 1.435) | 0.185 | ||||
| Peritumoral hypointensity on HBP | 5.889 (2.475, 14.01) | < 0.001 | 1.898 (0.528, 6.829) | 0.326 | 2.004 (0.717, 5.597) | 0.185 | ||
| Oval | 0.952 (0.315, 2.879) | 0.931 | 1.533 (0.515, 4.567) | 0.443 | 3.08 (0.82, 11.572) | 0.096 | ||
| Lobulated | 1.301 (0.614, 2.755) | 0.492 | 3.226 (1.4, 7.435) | 0.006 | 5.282 (1.962, 14.22) | |||
| Irregular | 1.333 (0.539, 3.301) | 0.534 | 1.971 (0.757, 5.136) | 0.165 | 2.188 (0.71, 6.741) | 0.173 | ||
Diagnostic performance
| Methods | Sensitivity | Specificity | Accuracy (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|
| Tumor size | 35.00 (21/61) | 80.00 (92/115) | 64.57 | 47.73 | 70.23 |
| HBsAg | 91.67 (55/60) | 18.26 (21/115) | 43.43 | 36.91 | 80.77 |
| Tumor Number | 28.33 (17/60) | 88.70 (102/115) | 68.00 | 56.67 | 70.34 |
| Capsule | 78.33 (47/60) | 39.13 (45/115) | 52.57 | 40.17 | 77.59 |
| Arterial peritumoral enhancement | 31.67 (19/60) | 96.52 (111/115) | 74.29 | 82.61 | 73.03 |
| Tumor margin | 76.67 (46/60) | 53.04 (61/115) | 61.14 | 46.00 | 81.33 |
| Series connection* | 0.00 (0/60) | 100.00 (115/115) | 65.71 | – | 65.71 |
| Parallel connection# | 100.00 (60/60) | 0.87 (1/115) | 34.86 | 34.48 | 100.00 |
| Tumor Number | 21.26 (27/127) | 93.75 (45/48) | 41.14 | 90.00 | 31.03 |
| Cirrhosis | 31.50 (40/127) | 87.50 (42/48) | 46.86 | 86.96 | 32.56 |
| Capsule | 72.44 (92/127) | 47.92 (23/48) | 65.71 | 78.63 | 39.66 |
| shape | 72.44 (92/127) | 47.92 (23/48) | 65.71 | 78.63 | 39.66 |
| Series connection* | 0.00 (0/127) | 100.00 (48/48) | 27.43 | – | 27.43 |
| Parallel connection# | 100.00 (127/127) | 2.08 (1/48) | 73.14 | 72.99 | 100.00 |